Basic Information
| LncRNA/CircRNA Name | CCAT2 |
| Synonyms | NA |
| Region | GRCh38_8:127400399-127402150 |
| Ensemble | ENSG00000280997 |
| Refseq | NR_109834 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | osteosarcoma |
| ICD-0-3 | NA |
| Methods | qPCR, Western blot |
| Sample | osteosarcoma tissues, cell lines (SAOS-2, MG63, and U2-OS) |
| Expression Pattern | up-regulated |
| Function Description | CCAT2 expression was significantly upregulated in OS tissues compared to adjacent normal bone tissues. Higher lncRNA CCAT2 expression positively associated with larger tumor size, advanced tumor stage and poor overall survival (OS) rate of patients. In vitro, knockdown of lncRNA CCAT2 suppressed cell proliferation and colony formation ability. In contrast, overexpression of lncRNA CCAT2 showed promoting cell proliferation effects in OS. Also, we found that knockdown of lncRNA CCAT2 inhibited GSK3?/?-catenin signaling by reducing p-GSK3? and ?-catenin expression, but increasing GSK3? expression. |
| Pubmed ID | 29863240 |
| Year | 2018 |
| Title | LncRNA CCAT2 Enhances Cell Proliferation via GSK3?/?-catenin Signaling Pathway in Human Osteosarcoma |
External Links
| Links for CCAT2 | GenBank HGNC NONCODE |
| Links for osteosarcoma | OMIM COSMIC |